Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcript March 9, 2024 Oncolytics Biotech Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to Oncolytics Biotech’s Fourth Quarter and Full Year 2023 Conference Call. All participants […]
Using hospital records of 34 million adults admitted to hospitals in England, Marlous Hall and team examine the long-term risk of major health outcomes following myocardial infarction.
KEYNOTE-564 is the first trial to demonstrate an overall survival benefit with adjuvant immunotherapy in patients with clear cell renal cell carcinoma.